Background Information

Executive Summary
Lundbeck (www.lundbeck.com), founded in 1915, is the only fully integrated pharmaceutical company focusing entirely on finding new and effective therapies for central nervous system (CNS) disorders. This strategic focus allows Lundbeck to establish strong links with academics, clinicians and patients with interests in CNS disorders.

Since 2002, Lundbeck has marketed four new pharmaceuticals – Cipralex®/Lexapro® for the treatment of depression and anxiety, Ebixa® for the treatment of Alzheimer’s disease, Azilect® for the treatment of Parkinson’s disease and Serdolect® for the treatment of schizophrenia.

In terms of revenue, Cipralex®/Lexapro® is Lundbeck’s largest pharmaceutical, followed by Ebixa®. Both pharmaceuticals were launched in the first markets in 2002. Since being launched in 2005, Azilect® has exceeded management’s sales expectations, while Serdolect®, launched in 2006, has fallen short of expectations. Lundbeck expects to launch its new pharmaceutical Circadin® for the treatment of primary insomnia in the first markets in 2008.

Lundbeck’s mature pharmaceuticals represent a stable foundation for consolidated revenue, with the exception of citalopram, the revenue of which continued to decline in 2007 due to generic competition. Lundbeck expects that citalopram revenue will continue to decline in 2008, albeit at a slower pace than previously.

Lundbeck is truly dedicated to research & development and has a long history of creating innovative CNS therapies, using latest research and product development technologies.

Cipralex®/Lexapro® (escitalopram)
– depression and anxiety
Cipralex®/Lexapro® is the most frequently prescribed branded pharmaceutical for the treatment of depression, both in the USA and in Europe and the second most prescribed in International Markets.

Since the 1950's, Lundbeck has had a strong position in the market for antipsychotic drugs and was one of the first companies to develop and market several effective antipsychotic treatments. With the development of Serdolect® (sertindole), Lundbeck also became a front-runner in the development of atypical antipsychotic drugs. Lundbeck has two other atypical antipsychotic drug candidates in its pipeline.

Besides being specialists in psychiatry, Lundbeck also aims to be specialists in neurology. Over the last five years, Lundbeck has built a strong product portfolio and pipeline in neurology with compounds for the treatment of Alzheimer’s disease and Parkinson’s disease. Ebixa® (memantine) for the treatment of Alzheimer’s disease is Lundbeck’s first major neurological product and is the first compound in an innovative therapeutic class. Azilect® (rasagiline) was the second drug in the neurological product portfolio when it was launched in 2005.

A key part of Lundbeck’s mission is to create partnerships with psychiatrists and neurologists that result in the improved treatment and hence improved quality of life for patients suffering from CNS disorders. As part of this commitment, Lundbeck established the Lundbeck Institute in 1997, which is dedicated to educating physicians from around the world who are involved in treating CNS disorders.

Lundbeck is a dynamically growing company with a strong financial track record. It has evolved from a Danish midsize enterprise in 1990 with around 1,000 employees to be a true global player with representations in 54 countries worldwide. Today, more than 5,300 people work at Lundbeck.

Key Facts

• Lundbeck is the only fully integrated pharmaceutical company focusing entirely on developing drugs to treat disorders of the central nervous system.
• Lundbeck uses the latest research and product development technologies to develop new and improved therapies for CNS disorders.
• Cipralex/Lexapro® (escitalopram) for the treatment of depression and anxiety was developed by Lundbeck and is the most frequently prescribed branded antidepressant in Europe and the USA.
• Azilect® (rasagiline) for the treatment of Parkinsons’ disease was developed in collaboration with Teva Pharmaceutical Industries Ltd. Lundbeck currently markets Azilect® in 24 countries.
• Ebixa® (memantine) for the treatment of moderate to severe Alzheimer’s disease was developed in collaboration with Merz Pharmaceuticals GmbH. Memantine is the second most prescribed pharmaceutical for the treatment of Alzheimer’s disease
  in the world.
• Serdolect® (sertindole) for the treatment of schizophrenia was developed by Lundbeck and has been launched in 28 countries since 2006.
• Lundbeck is dedicated to improving the quality of life of patients suffering from CNS disorders through partnerships with the healthcare professionals who treat them.

Specialisation in CNS
Lundbeck, based in Copenhagen, Denmark, is dedicated to the research and development, production, marketing and sale of ethical products for the treatment of CNS disorders. These disorders are the categorised as either psychiatric or neurological.

Psychiatric conditions of interest to Lundbeck include:

• Depression
• Schizophrenia
• Anxiety disorders

Within neurology, the company is currently focusing on:

• Parkinson’s disease
• Alzheimer’s disease
• Sleep disorders

Europe is Lundbeck’s home market, where Lundbeck’s status as a CNS specialist is broadly recognised amongst leading experts.

Through strategic alliances and own operations Lundbeck has access to all major pharmaceutical markets around the globe.

In 2007 the company’s revenue was DKK 10,985 million and profit from operations amounted to DKK 2,695 million.
 
Longstanding commitment to the treatment of CNS diseases
Lundbeck has been at the forefront of psychopharmacology since the 1950’s. The company’s pioneering antipsychotic, Truxal® (chlorprothixene) drove the company’s early growth after its introduction in the late 1950’s. At the company’s Golden Jubilee celebration in 1965, Lundbeck received praise for its efforts to improve the quality of life for people suffering from mental illness and for financial support of medical research.

Saroten®  (amitriptyline) was Lundbeck’s first antidepressant, introduced in the 1960’s. Saroten® is a tricyclic antidepressant (TCA), a substance group that used to be the standard treatment of depression prior to the introduction of the SSRIs. Lundbeck then extended its TCA portfolio by developing a complete range of products including Noritren® (nortriptyline) and Tymelyt® (lofepramine). Other of the company’s key products include Clopixol® (zuclopenthixol) and Fluanxol® (flupenthixol), both indicated for the treatment of schizophrenia and other psychotic disorders.

A company dedicated to R & D
Lundbeck is using the latest cutting-edge technologies in this search for new effective therapies against CNS disorders. Each year, Lundbeck invests around 20% of its revenue in R&D. Lundbeck’s research has strengthened considerably over the years with the appointment of highly qualified research scientists and the establishment of new technological and research facilities at Lundbeck headquarters.

In 2003 Lundbeck acquired the pharmaceutical company Synaptic with 110 employees. Hereby Lundbecks leadership position in CNS research and development was enhanced and Lundbeck Research US which is the current name provides a US-base for Lundbecks research and development.

Partnering with CNS Professionals to Improve Patient Quality of Life
Lundbeck has a number of initiatives ongoing to create alliances with healthcare professionals to advancing the overall treatment of CNS disorders.

The Lundbeck Institute
The mission of the Lundbeck Institute is primarily to educate healthcare professionals in evidence-based treatment of CNS disorders, while also building a network of physicians from around the world in order to keep up the level of knowledge and information transfer among these caregivers. So far more than 3,300 participants from all over the world, mostly psychiatrists and neurologists, have benefited from this unique educational opportunity. The content of many of the educational programmes at the Institute are accredited by independent Continuous Medical Education (CME) organisations. The Institute’s internet site, www.CNSforum.com, offers a good overview on the workshop contents and the course evaluations from former participants are also available.
  
For further information please contact:

Anders Schroll
Head of Corporate Communication
H. Lundbeck A/S
Ottiliavej 9
2500 Valby, Denmark
Tel: +45 36 43 20 81
E-mail: asch@lundbeck.com